Biological Basis for Understanding Psychopharmacology

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/27

flashcard set

Earn XP

Description and Tags

Vocabulary flashcards covering key concepts, neuroimaging techniques, neurotransmitters, and psychotropic drug classes from Chapter 4.

28 Terms

1
New cards

Positron-Emission Tomography (PET) and SPECT

Neuroimaging techniques that localize brain regions associated with perceptual, cognitive, emotional, and behavioral functions, providing evidence of metabolic changes in unmedicated individuals with depression, schizophrenia, or OCD.

2
New cards

Functional Magnetic Resonance Imaging (fMRI)

A neuroimaging technique that measures how well two regions of the brain communicate with each other, demonstrates cognitive function, and may eventually predict treatment response to medications.

3
New cards

Reuptake

The process by which a neurotransmitter, after interacting with the postsynaptic receptor, is released from the receptor and taken back into the presynaptic cell.

4
New cards

Receptor Agonist

An extrinsic drug that binds to and controls a cell receptor, producing the same biological effect as intrinsic substances.

5
New cards

Receptor Antagonist

An extrinsic drug that binds to a receptor site and blocks it, preventing intrinsic substances from binding.

6
New cards

Pharmacokinetic Drug Interactions

Interactions that occur when one drug alters the absorption, distribution, metabolism, or elimination of another drug, thereby affecting its plasma concentrations.

7
New cards

Pharmacodynamic Drug Interactions

Interactions that occur when drugs act at the same or interrelated receptor sites, resulting in synergistic or antagonistic effects.

8
New cards

Polypharmacy

The concurrent use of multiple medications by a patient, which complicates the management of drug interactions, especially in older adults.

9
New cards

Monoamine Oxidase (MAO)

An enzyme that destroys monoamine neurotransmitters, including catecholamines and indolamines.

10
New cards

Monoamine Oxidase Inhibitors (MAOIs)

Antidepressant drugs such as phenelzine, tranylcypromine, and transdermal selegiline that increase concentrations of monoamines by inhibiting the MAO enzyme.

11
New cards

Hypertensive Crisis

A severe adverse reaction occurring when a patient taking MAOIs ingests tyramine-containing foods (such as aged cheese, beer, wine, organ meats, and avocados) or certain OTC medications.

12
New cards

Antidepressant Discontinuation Syndrome

A withdrawal syndrome caused by abruptly stopping SSRIs, characterized by the FINISH mnemonic: Flu-like symptoms, Insomnia (with vivid dreams), Nausea, Imbalance (dizziness/vertigo), Sensory disturbances, and Headaches.

13
New cards

Serotonin Syndrome

A potentially life-threatening condition caused by excessive serotonin activity (mnemonic SHIVERS: Shivering, Hyperreflexia, Increased temperature, Vital sign instability, Encephalopathy, Restlessness, Sweating), treated with cyproreptadine.

14
New cards

Anticholinergic Toxidrome

A collection of side effects resulting from muscarinic cholinergic receptor blockade, summarized as 'Blind as a bat' (mydriasis), 'Mad as a hatter' (confusion), 'Red as a beet' (flushed skin), 'Hot as a desert' (hyperthermia), and 'Dry as a bone' (dry mouth, urinary retention).

15
New cards

Buspirone (Buspar)

An anxiolytic drug that reduces anxiety without producing the sedative and euphoric effects associated with benzodiazepines.

16
New cards

Z-hypnotics

Short-acting nonbenzodiazepine sedative-hypnotic sleep agents (zolpidem, zaleplon, eszopiclone) that provide sedative effects without the antianxiety, anticonvulsant, or muscle relaxant effects of benzodiazepines.

17
New cards

Ramelteon (Rozerem)

A melatonin-receptor agonist hypnotic drug thought to regulate circadian rhythms.

18
New cards

Lithium Blood Level Thresholds

Blood concentration parameters for lithium therapy: acute therapeutic level of 1 to 1.5 mEq/L, maintenance level of 0.6 to 1.2 mEq/L, and toxic level above 2.0 mEq/L.

19
New cards

Lamotrigine (Lamictal)

An anticonvulsant mood stabilizer effective in bipolar depression that carries a risk of triggering Stevens-Johnson syndrome (SJS), a severe skin reaction.

20
New cards

Carbamazepine (Tegretol)

An anticonvulsant mood stabilizer effective for rapid cycling bipolar disorder that may cause rare but serious blood dyscrasias.

21
New cards

Positive Symptoms of Schizophrenia

Psychotic symptoms that are present and should not be there, including visual and auditory hallucinations, delusional thinking, disorganized behavior and speech, and agitated or repetitive movements.

22
New cards

Negative Symptoms of Schizophrenia

The absence of normal behavioral functions that should be present, including flat or blunted affect, isolation, apathy, anergia, anhedonia, and reduced speech.

23
New cards

First-Generation Antipsychotics (FGAs)

Conventional antipsychotics (e.g., haloperidol, fluphenazine, chlorpromazine) that act as D2 dopamine receptor antagonists to reduce positive symptoms, but carry a significant risk of extrapyramidal side effects.

24
New cards

Extrapyramidal Side Effects (EPS)

Drug-induced movement disorders resulting from dopamine blockade, including pseudoparkinsonism, acute dystonia, akathisia, and tardive dyskinesia.

25
New cards

Akathisia

An extrapyramidal side effect characterized by motor restlessness, trouble standing still, pacing, and constant movement of the feet or rocking back and forth.

26
New cards

Tardive Dyskinesia

A late-onset extrapyramidal side effect characterized by involuntary movements such as tongue protrusion and rolling, lip sucking and smacking, chewing motions, and facial or extremity dyskinesia.

27
New cards

Neuroleptic Malignant Syndrome (NMS)

A rare, life-threatening adverse reaction to antipsychotics defined by the NMS Tetrad: altered mental status (AMS), hyperthermia (temp), autonomic instability, and muscular rigidity.

28
New cards

Second-Generation Antipsychotics (SGAs)

Atypical antipsychotics (e.g., clozapine, olanzapine, risperidone, quetiapine) that target both positive and negative schizophrenia symptoms with lower EPS risk, but carry a risk of metabolic syndrome.